Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05480774
Other study ID # BMRI-CT-2021-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 6, 2022
Est. completion date December 31, 2022

Study information

Verified date July 2022
Source Centre of Clinical Pharmacology, Hanoi Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a placebo-controlled, randomized, double-blind, multiple dose study that evaluated the safety, tolerability, and changes in indicators of immune function of Korean Red Ginseng Extract in Vietnamese healthy subjects following oral administration of multiple dose of Korean Red Ginseng Extract as hard capsules or placebo to healthy adult men.


Recruitment information / eligibility

Status Completed
Enrollment 101
Est. completion date December 31, 2022
Est. primary completion date December 3, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy adult male or female aged 20 to 65 years, inclusive at the time of informed consent - Have not any abnormalities of vital signs (temperature, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and pulse rate), physical examinations, clinical laboratory tests (hematology, chemistry, and urinalysis). - Ability and willingness to provide written informed consent and to comply with the requirements of the protocol. - Peripheral white blood cells in the range of 3000 - 10,000/µL - Subjects with a history of being infected with COVID-19 within 12 months according to the diagnostic criteria of the Ministry of Health at the time of infection Exclusion Criteria: - Pregnancy or lactation - For subjects of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception - Evidence of clinically significant acute or chronic hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psych, neurological, or neoplastic diseases (however, at the discretion of the principal investigator, subjects may also be considered) - Uncontrolled hypertension (SBP =160 mmHg and/or DBP =100 mmHg, measured following at least 10 mins of rest) - Uncontrolled diabetes (fasting glucose level above 126 mg/dL or diabetic patients who have initial treatment with antidiabetic drugs for = 3 months) - Aspartate aminotransferase or alanine aminotransferase >=3.0 × upper limit of normal - Serum creatinine level > 2,4 mg/dL for male and > 1,8 mg/dL for female - Use of medications and dietary supplements that can affect immunity within 2 weeks before screening - Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion - History of sensitivity or allergy to investigational product-related foods - Plan to participate in other research while participating in this research - Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study. - Failure of follow instructions for discontinuing immune-affecting dietary supplements during the wash-out period prior to trial participation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KRG hard capsule
Each subject was given orally 2 KRG hard capsules/day for 12 weeks
Placebo hard capsule
Each subject was given orally 2 placebo hard capsules/day for 12 weeks

Locations

Country Name City State
Vietnam Centre of Clinical Pharmacology Hanoi

Sponsors (3)

Lead Sponsor Collaborator
Centre of Clinical Pharmacology, Hanoi Medical University HK inno.N Corporation, Kyunghee University

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events associated with the administration of KRG Frequency and characteristics of adverse events associated with the administration of KRG 12 weeks
Secondary Natural killer (NK) cell count Change in NK cell count after 12 weeks compared to baseline 12 weeks
Secondary White blood cell count Change in white blood cell count after 12 weeks compared to baseline 12 weeks
Secondary Interferon (IFN)-a, ß, ? levels Changes in IFN-a, ß, ? levels after 12 weeks compared to baseline 12 weeks
Secondary Tumor necrosis factor (TNF)-a, ß, ? levels Changes in TNF-a, ß, ? levels after 12 weeks compared to baseline 12 weeks
Secondary Interleukin (IL)-1, 4, 6 levels Changes in IL-1, 4, 6 levels after 12 weeks compared to baseline 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1